Market News & Trends
Anti-Properdin Antibody Demonstrates Efficacy in a Primate Model of Wet-AMD & Dry-AMD
NovelMed Therapeutics recently announced NM3086, the lead clinical asset in its Properdin-associated Alternative Pathway (AP) program, demonstrated favorable efficacy in an animal model of neovascular…
Choosing the Best Drug Stability Solution for a Parental Product
The development of an injectable drug product always comes with the question of the best approach to retaining the product’s stability. We asked Dr. David Brett, Product and Service Manager at Vetter, what must be considered to deal with the….
Checkpoint Therapeutics Announces FDA Filing Acceptance of BLA for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
Checkpoint Therapeutics, Inc. recently announced the US FDA has accepted for filing the Biologics License Application (BLA) for cosibelimab, Checkpoint’s investigational anti-PD-L1 antibody….
Avenue Therapeutics Enters Transformational License Agreement With AnnJi Pharmaceutical
Avenue Therapeutics, Inc. recently announced it has entered into an exclusive license agreement with AnnJi Pharmaceutical Co., Ltd. for AJ201, a first-in-class clinical asset currently…
SiSaf & the University of Leipzig Partner to Develop Bio-Courier Targeted miRNA for the Treatment of Pancreatic Cancer
SiSaf Ltd recently announced its collaboration with the University of Leipzig, Germany, to develop Bio-Courier targeted micro interfering RNAs (miRNA) for the treatment of….
EPO Decision to Grant European Patent for Rencofilstat Further Strengthens Hepion’s Patent Portfolio
Hepion Pharmaceuticals, Inc. recently announced the European Patent Office (EPO) has granted European Patent No. EP 3886813, covering the innovative formulation of Hepion’s lead cyclophilin…
ImmunoGen Announces a Global, Multi-Target License & Option Agreement With Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents
ImmunoGen, Inc. recently announced a global, multi-target license and option agreement whereby it granted Vertex Pharmaceuticals rights to conduct research using ImmunoGen's ADC technology to…
Incannex Commences Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain & Function in Rheumatoid Arthritis
Incannex Healthcare Limited recently announced it has commenced a Phase 2 clinical trial to assess the safety and efficacy of its proprietary anti-inflammatory combination drug….
Incyclix Bio Announces FDA Clearance of IND Application for INX-315 in Patients With Advanced or Metastatic Cancer
Incyclix Bio, LLC recently announced the US FDA has cleared an investigational new drug (IND) application for the company’s lead compound, INX-315, a novel, potent…
QSAM Biosciences Completes Enrollment of Initial Cohort in its Phase 1 Study of CycloSam Targeting Metastatic Bone Cancer
QSAM Biosciences Inc. recently announced the completion of enrollment in the first participant grouping (cohort) of its Phase 1 study evaluating CycloSam in the treatment…
Absci Expands in Europe With Launch of New Innovation Center & Additional Senior Leadership in Switzerland
Absci Corporation recently announced its expansion into the European pharmaceutical market with the opening of its Innovation Center, located in Zug, Switzerland. The Zug Innovation…
EyePoint & Rallybio Announce Research Collaboration
Rallybio Corporation and EyePoint Pharmaceuticals, Inc recently announced a research collaboration. The partnership will evaluate sustained delivery of Rallybio’s inhibitor of complement component….
PDS Biotech Completes Successful Meeting With FDA for Triple Combination of PDS0101, PDS0301 & a Commercial Immune Checkpoint Inhibitor
Received guidance on registrational path for combination in recurrent/metastatic, immune checkpoint inhibitor refractory head and neck cancer….
IMUNON & Break Through Cancer Commence Enrollment in a Phase 1/2 Clinical Study of IMNN-001 in Combination With Avastin in Advanced Ovarian Cancer
IMUNON, Inc. and Break Through Cancer recently announced the commencement of patient enrollment in a collaboration to evaluate IMUNON’s IMNN-001 (formerly GEN-1) in combination with…
Nexcella Announces Patients Already Treated With CAR-T NXC-201; Estimates 100-Patient Total Enrollment for FDA Approval BLA Submission
Nexcella, Inc. recently announced 50 relapsed/refractory multiple myeloma patients have already been dosed with next-generation CAR-T NXC-201 in its ongoing Phase 1b/2a clinical trial. Nexcella…
Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. & Portfolio of Investigational Therapeutics
Rhythm Pharmaceuticals, Inc. recently announced Rhythm’s Netherlands subsidiary, Rhythm Pharmaceuticals Netherlands B.V., acquired Xinvento B.V., a Netherlands-based biotech company focused on developing therapies for congenital…
Redx & Jounce Announce Recommended Business Combination
Redx Pharma and Jounce Therapeutics, Inc. recently announce an unanimously recommended Business Combination of the two companies via a proposed all share merger transaction. Redx…
VBL Therapeutics & Notable Labs Announce Definitive Merger Agreement
VBL Therapeutics and Notable Labs, Inc. recently announced they have entered into a definitive merger agreement. The combined company will focus on the advancement of…
BriaCell Reports Positive Survival Data in Advanced Metastatic Breast Cancer
BriaCell Therapeutics Corp. recently reported updated survival data from its previously disclosed group of 12 patients (11 patients enrolled in 2021/2022) in the ongoing Phase…
Ocean Biomedical Celebrates Discovery of Bispecific Antibodies & Immune Checkpoint Inhibitors That Kill Glioblastoma Cells & Melanoma Cells & Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%
Ocean Biomedical, Inc. celebrates the discovery of bispecific antibodies that target Chitinase 3-like-1 and immune checkpoint inhibitors, killing glioblastoma cells and melanoma cells, and blocking the metastasis of malignant….
